<DOC>
	<DOCNO>NCT00496847</DOCNO>
	<brief_summary>PERIOGEN , contain rhPDGF -beta-TCP , promote gingival heal corrects periodontal defect . This study test safety efficacy PERIOGEN treatment periodontal disease</brief_summary>
	<brief_title>Efficacy Safety PERIOGEN Treatment Periodontal Bone Defect</brief_title>
	<detailed_description>Sixty eligible patient periodontal defect randomly receive either beta-TCP implantation ( control group ) PERIOGEN implantation , contain beta-TCP rhPDGF ( drug group ) . The specified primary secondary end point related efficacy safety assess 6 month study period .</detailed_description>
	<criteria>1 . Probing depth ≥7 mm baseline 2 . Presence ≥4 mm vertical bone defect least 1 bony wall surgical debridement . 3 . Adequate keratinize tissue permit complete tissue coverage defect . 4 . Radiographic base defect ≥3 mm coronal apex tooth . 1 . Failure maintain adequate oral hygiene ( plaque index &gt; 2 ) 2 . Pregnant lactate woman 3 . History oral cancer HIV 4 . Periodontal surgery treatmenttargeted tooth within last year . 5 . Tooth mobility great grade II . 6 . Study tooth exhibit class III furacation defect 7 . Localized aggressive periodontitis 8 . Radiographic sign untreated acute infection surgical site 9 . Recent history smoke 20 cigarettes/day 10 . Known allergy E.coliderived product 11 . Using investigational therapy within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>rhPDGF ,</keyword>
	<keyword>periodontal disease</keyword>
</DOC>